Yi-Bin Chen, MD

Articles

Graft Versus Host Disease: Optimizing Prophylaxis Techniques

July 11th 2022

Shared insight on standard-of-care prophylactic methods employed in the management of patients with graft versus host disease.

Understanding Pathophysiology and Risk of Graft Versus Host Disease

July 11th 2022

Expert panelists spearhead a discussion on the pathophysiology driving both acute and chronic graft versus host disease.

Emerging Treatment Strategies for Chronic GVHD

May 13th 2022

Closing out their discussion on graft-versus-host disease, experts Yi-Bin Chen, MD, and Corey Cutler, MD, MPH, FRCPC, share excitement for future treatment strategies.

HSCT Approaches to Retain GVL While Preventing GVHD

May 6th 2022

Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.

Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials

May 6th 2022

Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.

Chronic GVHD: Novel Treatment Approaches With Approved Agents

April 29th 2022

Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.

Selecting Second-Line Therapy for Chronic GVHD

April 29th 2022

Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.

Chronic GVHD: Real-World Use of Ruxolitinib

April 22nd 2022

Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.

REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

April 22nd 2022

Comprehensive insight on the design and results of REACH3, which analyzed ruxolitinib as second-line therapy for chronic graft-vs-host disease.

Mechanism of Action of Ruxolitinib

April 15th 2022

In the context of chronic graft-vs-host disease, expert Yi-Bin Chen, MD, provides an overview of ruxolitinib’s mechanism of action.

Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

April 15th 2022

Haris Ali, MD, shares insight on belumosudil, a ROCK2 inhibitor approved in the management of chronic graft-vs-host disease.

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

April 8th 2022

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Identifying and Managing Steroid-Refractory Chronic GVHD

April 8th 2022

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Defining Steroid-Refractory and Steroid-Dependent GVHD

April 1st 2022

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

Frontline Treatment Options for Chronic GVHD

April 1st 2022

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.

Acute vs Chronic GVHD: Identification and Stratification

March 25th 2022

Insight on the identification of acute versus chronic graft-versus-host disease, including best diagnostic and risk stratification practices.

Background on Graft-vs-Host Disease: Risk Factors and Prevention

March 25th 2022

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft-versus-host disease, followed by insight on standard disease prevention practices.

Unmet Needs in GVHD Management

February 22nd 2022

Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.

Supportive Care for Steroid-Refractory Chronic GVHD Treatment

February 22nd 2022

Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.

Clinical Manifestations of Chronic GVHD

February 22nd 2022

Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.